Tissue Regenix ‘well positioned’ – Odell

MEDICAL device firm Tissue Regenix believes it is well place to capitalise on the growing demand for regenerative health technology.

Half-year pre-tax losses for the company rose to £1.26m, from £578,000 last year without the costs of the Oxeco reverse acquisition, as it invested in broadening its product range.

York-based Tissue Regenix’s dCELL technology helps to prevent the body rejecting tissues. The company received approval last year for a blood vessel patch made from pig tissue.

Antony Odell, Tissue Regenix’s managing director, said: “Tissue Regenix has continued to build on last year’s achievements by further adding to our clinical data in support of the dCELL® Platform as well as  concluding a deal with our Brazilian development partners that will enable us to develop our technology faster and more cost effectively. 

“Additionally, through this deal we have opened up new opportunities with the acquisition of the global rights (excluding Brazil) to a pipeline of innovative products, including a number of potential near-term revenue generating opportunities. 

“With exciting new products in development and a healthy financial position, we believe we are well positioned for growth within the exciting regenerative medicine space.”

Revenues at the company held steady in the first half of the year at £108,000 compared to £112,000 in 2010.